Cargando…
Preclinical evaluation of ribociclib and its synergistic effect in combination with alpelisib in non-keratinizing nasopharyngeal carcinoma
Ribociclib is a specific cyclin dependent kinase (Cdk) 4/6 inhibitor that induces G(1) arrest by blocking the formation of cyclin D1-Cdk4/6 complex and inhibiting retinoblastoma (RB) phosphorylation. Cyclin D1 is overexpressed in over 90% of nasopharyngeal carcinoma (NPC) and CCND1 gene activation p...
Autores principales: | Wong, Chi-Hang, Ma, Brigette B. Y., Hui, Connie W. C., Lo, Kwok-Wai, Hui, Edwin P., Chan, Anthony T. C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5964240/ https://www.ncbi.nlm.nih.gov/pubmed/29789630 http://dx.doi.org/10.1038/s41598-018-26201-1 |
Ejemplares similares
-
Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response
por: Ma, Brigette B.Y., et al.
Publicado: (2009) -
Erratum to: Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response
por: Ma, Brigette B. Y., et al.
Publicado: (2010) -
Radiological, pathological and DNA remission in recurrent metastatic nasopharyngeal carcinoma
por: Chan, Stephen L, et al.
Publicado: (2006) -
A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer
por: Jhaveri, Komal, et al.
Publicado: (2021) -
Diabetic Ketoacidosis With Alpelisib
por: Jeun, Rebecca, et al.
Publicado: (2021)